• Egypt becomes the sixth country in the world to achieve self-sufficiency in plasma-derived medicines
• A firm commitment to enhancing Egypt’s healthcare system
• Adhering to the highest international quality standards strengthens Grifols Egypt’s international position and supports the Egyptian economy

Cairo, December 2025: Grifols Egypt for Plasma Derivatives — an Egyptian joint venture established through a partnership between the Egyptian government, represented by the National Service Projects Organization (NSPO), and Grifols, the global leader in plasma-derived medicines and innovative healthcare solutions — announced that its integrated plasma value chain has obtained certification from the European Medicines Agency (EMA).

This certification covers all aspects of plasma operations, including plasma donation, laboratory testing, cold-chain management, and plasma transport. Egyptian plasma has also been included in Europe’s Plasma Master File (PMF). With this milestone, Grifols Egypt becomes the first company outside the United States and Europe to obtain EMA certification—affirming its compliance with global quality standards and strengthening its regional and international presence.

This achievement comes in concurrence with guidance of the President of the Arab Republic of Egypt to enhance the healthcare sector, achieve self-sufficiency in plasma-derived medicines, and support the national economy. Egypt has thus become the first regional hub in the Middle East and Africa with a fully integrated platform for localizing the plasma-derivatives industry—from plasma collection all the way to the production of the final medicinal products.

In this context, the Chairman of Grifols Egypt for Plasma Derivatives stated: “We are proud to obtain this certification, which represents five years of commitment to the highest standards of quality and safety.” He emphasized that the company’s strategy is focused on strengthening Egypt’s healthcare sector by ensuring the sustainable availability of plasma-derived medicines for patients. He added: “Thanks to the dedication of our donors and the awareness of the Egyptian people regarding the importance of this project, we have achieved 100% local self-sufficiency in human albumin, coagulation factors, and immunoglobulins—essential therapies that significantly improve the quality of life for thousands of patients with rare and chronic diseases. Egypt is now the sixth country in the world to reach self-sufficiency in this vital field.”

As part of completing the integrated plasma manufacturing platform, pilot operations have begun for the first phase of the plasma-derivatives manufacturing plant in the New Administrative Capital. Full operations of this phase are expected to commence in 2026, and will include a fully automated plasma logistics center, a central testing laboratory, and a warehouse for finished pharmaceutical products.